跳至主要内容
临床试验/CTRI/2026/04/107397
CTRI/2026/04/107397尚未招募不适用

A randomized controlled trial of comparing the effects of different adjuvants to hyperbaric Bupivacaine in subarachnoid block in patients undergoing lower limb orthopedic surgeries

Air Force Hospital1 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2026年4月6日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
138
试验地点
1

研究概览

简要总结

Based on current evidence, dexmedetomidine 5 µg as an intrathecal adjuvant to 0.5 hyperbaric bupivacaine offers several advantages

Faster onset of both sensory and motor blockade

Prolonged block duration and postoperative analgesia

Better hemodynamic stability

Minimal side effects compared to opioids like fentanyl or nalbuphine

It is a superior and safe adjuvant that enhances the quality and duration of spinal anesthesia in lower abdominal and lower limb surgeries

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Double

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Age more than 18 yrs.

排除标准

  • Infection at the site of injection Coagulopathy or anticoagulation Congenital anomalies of the lower spine Any preexisting neuropathy History of allergy to local anaesthetics.

研究者

发起方
Air Force Hospital
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Shaik Nagoor Vali

7 AIR FORCE HOSPITAL

研究点 (1)

Loading locations...

相似试验